Typical hospital ward in Nigeria. Twitter photo.
No fewer than 250,000 women are killed by cervical cancer every year with 85 per cent of them from low and middle income countries.
As stated by a report released on Thursday by the World Health Organisation (WHO), the deaths occur mainly in countries in Africa and Asia.
The agency underlined the importance of vaccinating girls against the cancer-causing virus and screening programmes to detect and treat precancerous lesions.
The agency also stressed the need to overcome cultural norms and dispel gender biases that are challenging the effectiveness of vaccination initiatives.
“In high-income countries, widespread screening has radically reversed the trends, and cervical cancer incidence and mortality have declined sharply [with] the impact of vaccination in reducing human papillomavirus (HPV)-related diseases is already being documented.
“However, in developing countries, where the burden of the disease is heaviest, cervical cancer control is often not seen as a priority within tight health budgets, and women are not given life-saving access to adequate prevention and treatment,” WHO added.
While HPV vaccination has shown it can protect women from chronic infection caused by HPV16 and HPV18 (both main types of the virus known to cause cervical cancer), vaccination programmes have not been implemented nationally in several low- and middle-income countries in Asia and Africa, it stated.
WHO stated.as a result, women are left vulnerable to the risk of developing cervical disease, which, given the inadequacy of screening and treatment services in several countries, is likely to go untreated.
Rolando Herrero, Head of Early Detection and Prevention Section at the International Agency for Research on Cancer (IARC), warned of the dangers of more women developing cancer in developing countries unless something urgent is done.
“Unless we act rapidly, thousands of women will develop cervical cancer because they are not vaccinated.
“In countries where early detection and screening are difficult to implement due to a lack of proper infrastructure, vaccination has a vital role to play in protecting women from cervical cancer,” Herrero stated.
He urged governments commitment to implement HPV vaccination regimes.
He added that in some regions, cultural norms and fear that “vaccination would promote s3xual activity” is also a barrier in vaccinating young girls as are low schooling rates, which could limit the reach of immunisation programmes, which often take place in schools.
Rengaswamy Sankaranarayanan, Special Advisor on Cancer Control and Head of IARC’s Screening Group, stressed: “On top of these hurdles, ‘gender bias’ and perception that ‘women are a less important population to invest in’ in several countries is making matters much worse.
“It is vital that governments address these barriers.
“In several countries, women are often the only breadwinners, and therefore protecting them is of huge human and economic importance,” he stated.
IARC Director Christopher Wild, also stressed the need to make vaccines cheaper, particularly for the developing countries, to step up vaccination coverage.
“Competition between potentially new and existing vaccine manufacturers is urgently needed in order to reduce costs and enable countries to better protect women against cervical cancer.”
The IARC is part of WHO responsible to coordinate and conduct research on the causes of human cancer, the mechanisms of carcinogenesis, and to develop scientific strategies for cancer control.
It is also involved in both epidemiological and laboratory research and dissemination of scientific information on the disease. (NAN)
- NAN